/* RM 168662 - Track viewing of recorded presentations */

The Autism Biomarkers Consortium for Clinical Trials: Study Design and Progress to Interim Analysis

J. McPartland1, S. J. Webb2, F. Shic3, A. Naples4, C. Sugar5, M. Murias6, J. Dziura7, C. Brandt8, R. A. Bernier9, K. Chawarska10, G. Dawson11, S. Faja12, S. Jeste13 and C. A. Nelson14, (1)Yale Child Study Center, Yale Child Study Center, New Haven, CT, (2)Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, (3)Center for Child Health, Behavior, and Development, Seattle Children's Research Institute, Seattle, WA, (4)Yale Child Study Center, Yale University School of Medicine, New Haven, CT, (5)Department of Biostatistics, University of California Los Angeles, Los Angeles, CA, (6)Duke Center for Autism and Brain Development, Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, (7)Emergency Medicine, Yale University School of Medicine, New Haven, CT, (8)Yale University, New Haven, CT, (9)Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, (10)Child Study Center, Yale University School of Medicine, New Haven, CT, (11)Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, (12)Boston Children's Hospital / Harvard Medical School, Brookline, MA, (13)Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA, (14)Department of Developmental Medicine, Boston Children's Hospital, Boston, MA